Prestige Consumer Healthcare Inc. PBH
We take great care to ensure that the data presented and summarized in this overview for Prestige Consumer Healthcare Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PBH
View all-
Black Rock Inc. New York, NY8.73MShares$606 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.74MShares$398 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.16MShares$219 Million0.06% of portfolio
-
Macquarie Group LTD Australia, C32.92MShares$203 Million0.24% of portfolio
-
Ariel Investments, LLC Chicago, IL2.56MShares$178 Million1.98% of portfolio
-
State Street Corp Boston, MA2.01MShares$140 Million0.01% of portfolio
-
Victory Capital Management Inc1.9MShares$132 Million0.14% of portfolio
-
Geode Capital Management, LLC Boston, MA1.2MShares$83.3 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.12MShares$77.5 Million0.02% of portfolio
-
Morgan Stanley New York, NY1.07MShares$74.2 Million0.01% of portfolio
Latest Institutional Activity in PBH
Top Purchases
Top Sells
About PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Insider Transactions at PBH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 07
2024
|
Ronald M. Lombardi Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,298
+4.26%
|
-
|
May 07
2024
|
Mary Beth Fritz SVP Quality & Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
2,042
+9.78%
|
-
|
May 07
2024
|
William P'Pool Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,123
+9.71%
|
-
|
May 07
2024
|
Christine Sacco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,062
+16.75%
|
-
|
May 07
2024
|
Jeffrey Zerillo Senior VP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
2,116
+4.85%
|
-
|
May 07
2024
|
Adel Mekhail EVP, Marketing & Sales |
BUY
Grant, award, or other acquisition
|
Direct |
3,020
+12.14%
|
-
|
May 06
2024
|
Christine Sacco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,363
-18.23%
|
$375,410
$70.0 P/Share
|
May 06
2024
|
Christine Sacco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,943
+27.11%
|
-
|
May 06
2024
|
Jeffrey Zerillo Senior VP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,951
-4.72%
|
$136,570
$70.0 P/Share
|
May 06
2024
|
Jeffrey Zerillo Senior VP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,894
+8.61%
|
-
|
May 06
2024
|
Ronald M. Lombardi Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,356
-11.88%
|
$2,894,920
$70.0 P/Share
|
May 06
2024
|
Ronald M. Lombardi Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,533
+99.59%
|
-
|
May 06
2024
|
Mary Beth Fritz SVP Quality & Regulatory |
SELL
Payment of exercise price or tax liability
|
Direct |
1,597
-8.68%
|
$111,790
$70.0 P/Share
|
May 06
2024
|
Mary Beth Fritz SVP Quality & Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
3,456
+15.82%
|
-
|
May 06
2024
|
Adel Mekhail EVP, Marketing & Sales |
SELL
Payment of exercise price or tax liability
|
Direct |
3,303
-14.91%
|
$231,210
$70.0 P/Share
|
May 06
2024
|
Adel Mekhail EVP, Marketing & Sales |
BUY
Grant, award, or other acquisition
|
Direct |
5,472
+19.81%
|
-
|
May 06
2024
|
William P'Pool Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,946
-10.21%
|
$206,220
$70.0 P/Share
|
May 06
2024
|
William P'Pool Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,737
+16.58%
|
-
|
May 03
2024
|
William P'Pool Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
642
-2.7%
|
$44,940
$70.0 P/Share
|
May 03
2024
|
Christine Sacco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-5.94%
|
$81,690
$70.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 159K shares |
---|---|
Exercise of conversion of derivative security | 118K shares |
Payment of exercise price or tax liability | 73.9K shares |
---|---|
Open market or private sale | 123K shares |